Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer

Journal of Urology

Volumn 165, Issue 6 I, 2001, Pages

  Waidelich, R ^a   Stepp, H ^a   Baumgartner, R ^a   Weninger, E ^a   Hofstetter, A ^a   Kriegmair, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aminolevulinic acid; Bladder; Carcinoma, transitional cell; Photochemotherapy

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; PHOTOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOTENSION; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SUPERFICIAL CANCER; TACHYCARDIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT FAILURE; BLADDER TUMOR; MIDDLE AGED; PHOTOCHEMOTHERAPY; TUMOR RECURRENCE;

ADULT; AGED; AMINOLEVULINIC ACID; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; URINARY BLADDER NEOPLASMS;

EID: 0034992420     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66239-8     Document Type: Article

References (24)

1. Report of a follow-up of papillary tumours of the bladder
2. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS)
3. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C
4. When intravesical measures fail
5. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer
6. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder
7. Laser photodynamic therapy for bladder cancer
8. Long-term experience with integral photodynamic therapy of TIS bladder carcinoma
9. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence
10. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy
11. Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: Enhancement by 1.10-phenanthroline
12. Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: Light diffusion and histological changes
13. Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model
14. Oral versus intravenous administration of 5-aminolevulinic acid for photodynamic therapy
15. Wavelength and light-dose dependence in tumour phototherapy with hematoporphyrin derivative
16. Canine bladder response to red and green light whole bladder photodynamic therapy
17. Green light photodynamic therapy in the human bladder
18. Wavelength dependent photodynamic effects on chemically induced rat bladder tumors following intravesical instillation of 5-aminolevulinic acid
19. The metabolism of 5-aminolevulinic acid
20. Cutaneous phototoxic occurrences in patients receiving photofrin
21. Hemodynamic effects of 5-aminolevulinic acid in humans
22. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer
23. The three-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer
24. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminium phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX